#1 Clinical Trials Search in Europe

Air, Medicinal

This article discusses clinical trials investigating the use of medicinal air in treating acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD). These trials aim to compare standard oxygen therapy with targeted oxygen therapy in prehospital settings for COPD patients. The research focuses on evaluating the effects of titrated oxygen strategies on patient outcomes, including mortality rates, respiratory function, and hospital admissions.

Table of Contents

What is Medicinal Air?

Medicinal air, also known as AIR, MEDICINAL or AIR MEDICINAL, is a compressed gas used for medical purposes[1]. It is a mixture of gases that mimics the composition of the air we breathe but is purified and prepared under controlled conditions to ensure its safety and efficacy for medical use. Medicinal air is classified as a pharmaceutical product and is subject to strict quality control measures.

Medical Conditions Treated

Medicinal air is primarily used in the treatment of respiratory conditions, with a particular focus on Chronic Obstructive Pulmonary Disease (COPD). Specifically, it is being studied for its potential benefits in managing Acute Exacerbations of COPD (AECOPD)[2].

COPD is a long-term lung disease that causes airflow blockage and breathing-related problems. An acute exacerbation is a sudden worsening of COPD symptoms, which can be life-threatening and often requires immediate medical attention.

How Medicinal Air is Used

Medicinal air is administered through inhalation[1]. It is typically delivered using specialized equipment that allows for controlled delivery of the gas. The exact dosage and duration of treatment can vary depending on the patient’s condition and the specific treatment protocol being followed.

In clinical trials, medicinal air is being studied as part of a titrated oxygen strategy. This means that the amount of oxygen given to a patient is carefully adjusted based on their individual needs, rather than providing a standard amount to all patients[2].

Clinical Trials and Research

Medicinal air is currently being studied in clinical trials, particularly in the context of treating AECOPD. One such trial is the STOP-COPD (Standard vs Targeted Oxygen Therapy Prehospital for Chronic Obstructive Pulmonary Disease) study[2].

The main objective of this trial is to determine whether using a titrated oxygen strategy in the prehospital setting (before the patient reaches the hospital) can reduce 30-day mortality in patients with suspected AECOPD compared to standard care[2].

Potential Benefits

The clinical trials are investigating several potential benefits of using medicinal air as part of a titrated oxygen strategy for AECOPD patients. These include:

  • Reduced mortality at 24 hours, 7 days, and 30 days after treatment[2]
  • Improved management of dyspnea (difficulty breathing or shortness of breath)[2]
  • Reduced need for non-invasive ventilation (NIV) or invasive ventilation in the hospital[2]
  • Reduced incidence and severity of respiratory acidosis (a condition where there’s too much carbon dioxide in the blood, making it more acidic)[2]
  • Reduced rate of admission to intensive care units (ICU)[2]
  • Shorter hospital and ICU stays[2]
  • Lower readmission rates[2]

Considerations and Precautions

While medicinal air is generally considered safe, it’s important to note that its use is being studied in controlled clinical trials. Some considerations include:

  • It’s typically used for patients over 40 years of age with suspected AECOPD[2]
  • It’s not recommended for patients with non-COPD bronchospasm, known or suspected pregnancy, or allergy to certain inhalation drugs (like Salbutamol)[2]
  • The maximum daily dose being studied is up to 2500 liters[1]
  • It should only be used under medical supervision and as part of a comprehensive treatment plan

As with any medical treatment, it’s crucial to follow the guidance of healthcare professionals and report any unusual symptoms or side effects promptly.

Aspect Details
Study Title STOP-COPD: Standard vs Targeted Oxygen Therapy Prehospital for Chronic Obstructive Pulmonary Disease
Main Objective Determine if prehospital titrated oxygen therapy reduces 30-day mortality in AECOPD patients
Key Inclusion Criteria Age > 40, suspected AECOPD, need for inhaled bronchodilators
Key Exclusion Criteria Non-COPD bronchospasm, pregnancy, advanced respiratory support needs
Primary Endpoint 30-day mortality
Secondary Endpoints 24-hour mortality, hospital/ICU stay length, ventilation needs, acidosis, dyspnea, readmission rates
Intervention Titrated oxygen therapy vs standard care
Medicinal Air Administration Inhalation, max daily dose 1000-2500 liters

FAQ

  • What is the main goal of these clinical trials using medicinal air? The main goal is to determine whether prehospital titrated oxygen therapy in patients with suspected acute exacerbation of COPD (AECOPD) will decrease 30-day mortality compared to patients receiving standard care.
  • Who can participate in these clinical trials? Participants must be over 40 years old, have a confirmed or suspected COPD exacerbation, and require inhaled bronchodilators. However, patients with non-COPD bronchospasm, pregnancy, or those requiring advanced respiratory support are excluded.
  • What are some of the secondary objectives of these trials? Secondary objectives include assessing the effect on dyspnea, reducing the need for hospital ventilation support, evaluating short-term mortality rates, and analyzing the impact on respiratory acidosis and hospital readmission rates.
  • How is medicinal air administered in these trials? Medicinal air is administered through inhalation. The trials compare a titrated oxygen strategy to standard care, with maximum daily doses ranging from 1000 to 2500 liters.
  • What outcomes are being measured in these clinical trials? The trials measure various outcomes, including 30-day mortality, 24-hour mortality, length of hospital and ICU stay, need for ventilation support, degree of respiratory acidosis, patient-experienced dyspnea, and readmission rates.

Ongoing Clinical Trials on Air, Medicinal

  • Study on Oxygen Therapy and Salbutamol for Patients with COPD Exacerbation

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Denmark

Glossary

  • COPD: Chronic Obstructive Pulmonary Disease, a long-term lung condition that causes breathing difficulties.
  • AECOPD: Acute Exacerbation of Chronic Obstructive Pulmonary Disease, a sudden worsening of COPD symptoms.
  • Titrated oxygen therapy: A method of administering oxygen where the amount is carefully adjusted based on the patient's needs and response.
  • Prehospital: Medical care provided before a patient reaches the hospital, typically by emergency medical services.
  • NIV: Non-Invasive Ventilation, a method of providing breathing support without inserting a tube into the airway.
  • Invasive ventilation: A form of breathing support that involves inserting a tube into the patient's airway.
  • Respiratory acidosis: A condition where the body produces too much carbon dioxide, leading to increased acidity in the blood.
  • Dyspnea: Difficulty breathing or shortness of breath.
  • ICU: Intensive Care Unit, a special department in hospitals that provides intensive care medicine.
  • Bronchodilators: Medications that relax and open the airways, making it easier to breathe.

References

  1. http://clinicaltrials.eu/trial/study-on-oxygen-therapy-and-salbutamol-for-patients-with-copd-exacerbation/
  2. http://clinicaltrials.eu/trial/study-on-oxygen-therapy-and-drug-combination-for-patients-with-acute-exacerbation-of-chronic-obstructive-pulmonary-disease-copd/